Core Insights - The company has successfully reduced the price of the innovative drug Koserla from $1,400 to 466 RMB, significantly benefiting patients in China [2] - The accelerated commercialization process of Koserla, taking only 13 months instead of the traditional 3 years, is attributed to the Boao Lecheng International Medical Tourism Pilot Zone's real-world data pilot program [2] - The local production of Koserla in Haikou is expected to enhance affordability and accessibility for patients, with an annual production capacity of 2 million units [3] - The company aims to leverage the Hainan Free Trade Port policies to expedite the international licensing of its self-developed products, with a total contract value of 745 million RMB for its first overseas project [3] Company Strategy - The company is utilizing the "Lecheng Research and Use + Haikou Production" model to integrate industrial foundations with policy advantages, facilitating the local production of international innovative drugs [3] - The company has already achieved three overseas patent technology authorizations for its self-developed products since the establishment of the Hainan Free Trade Port [3] - A significant drug export project worth several hundred million RMB is expected to be completed by the end of this year [3]